Development of bombesin peptide kit for prostate cancer diagnosis and treatment using 64Cu/177Lu. |
Kim, Mi Hyun
(RI-Convergence Research, Korea Institute of Radiological and Medical Sciences)
Kim, Min Hwan (RI-Convergence Research, Korea Institute of Radiological and Medical Sciences) Kim, Kwang Il (RI-Convergence Research, Korea Institute of Radiological and Medical Sciences) Kim, Jung Young (RI-Convergence Research, Korea Institute of Radiological and Medical Sciences) Lee, Tae Sup (RI-Convergence Research, Korea Institute of Radiological and Medical Sciences) Kang, Joo Hyun (RI-Convergence Research, Korea Institute of Radiological and Medical Sciences) Lee, Kyo Chul (RI-Convergence Research, Korea Institute of Radiological and Medical Sciences) Lee, Yong Jin (RI-Convergence Research, Korea Institute of Radiological and Medical Sciences) |
1 | Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29. DOI |
2 | Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-241. DOI |
3 | Zhang H, Desai P, Koike Y, Houghton J, Carlin S, Tandon N, Touijer K, Weber WA. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist. J Nucl Med 2017;58:29-35. DOI |
4 | Accardo A, Galli F, Mansi R, Del Pozzo L, Aurilio M, Morisco A, Ringhieri P, Signore A, Morelli G, Aloj L. Preclinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumors. EJNMMI Res 2016;6:17 DOI |
5 | Dalm SU, Martens JW, Sieuwerts AM, van Deurzen CH, Koelewijn SJ, de Blois E, Maina T, Nock BA, Brunel L, Fehrentz JA, Martinez J, de Jong M, Melis M. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer. J Nucl Med 2015;56:752-757. DOI |
6 | Roivainen A, Kahkonen E, Luoto P, Borkowski S, Hofmann B, Jambor I, Lehtio K, Rantala T, Rottmann A, Sipila H, Sparks R, Suilamo S, Tolvanen T, Valencia R, Minn H. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga-bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med 2013;54:867-872. DOI |
7 | Kahkonen E, Jambor I, Kemppainen J, Lehtio K, Grönroos TJ, Kuisma A, Luoto P, Sipila HJ, Tolvanen T, Alanen K, Silen J, Kallajoki M, Roivainen A, Schafer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res 2013;19:5434-5443. DOI |
8 | Kim MH, Park JA, Woo SK, Lee KC, An GI, Kim BS, Kim KI, Lee TS, Kim CW, Kim KM, Kang JH, Lee YJ. Evaluation of a 64Cu-labeled 1,4,7-triazacyclononane, 1-glutaric acid- 4,7 acetic acid (NODAGA)-galactose-bombesin analogue as a PET imaging probe in a gastrin‑releasing peptide receptor‑expressing prostate cancer xenograft model. Int J Oncol 2015;46:1159-1168. DOI |
9 | Stott Reynolds TJ, Schehr R, Liu D, Xu J, Miao Y, Hoffman TJ, Rold TL, Lewis MR, Smith CJ. Characterization and evaluation of DOTA-conjugated Bombesin/RGDantagonists for prostate cancer tumor imaging and therapy. Nucl Med Biol 2015;42:99-108. DOI |
![]() |